Today’s Research Reports on Hamilton Thorne, Hemostemix, Aeterna Zentaris and Medicure

NEW YORK, NY / ACCESSWIRE / April 24, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Hamilton Thorne Ltd.
https://rdinvesting.com/news/?ticker=HTL.V

Hemostemix Inc.
https://rdinvesting.com/news/?ticker=HEM.V

Aeterna Zentaris Inc.
https://rdinvesting.com/news/?ticker=AEZS.TO

Medicure Inc.
https://rdinvesting.com/news/?ticker=MPH.V

Hamilton Thorne’s stock moved 1.22% lower Monday, to close the day at $0.81. The stock recorded a trading volume of 134,048 shares, which was above its three months average volume of 88,145 shares. In the last year, Hamilton Thorne’s shares have traded in a range of 0.59 – 1.05. The share price has gained 37.29% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $0.77 is greater than its 200-day moving average of $0.76. Shares of the company are trading at a Price to Earnings ratio of 50.62. Shares of Hamilton Thorne have gained approximately 8 percent year-to-date.

Access RDI’s Hamilton Thorne Ltd. Research Report at:
https://rdinvesting.com/news/?ticker=HTL.V

On Monday, shares of Hemostemix recorded a trading volume of 1,019,300 shares, which was above the three months average volume of 312,025 shares. The stock ended the day 16.67% lower at 0.07. The share price has gained 66.67% from its 52 week low with a 52 week trading range of 0.05 – 0.16. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $0.06 is below its 200-day moving average of $0.07. Shares of Hemostemix have gained approximately 7.14 percent year-to-date.

Access RDI’s Hemostemix Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HEM.V

Aeterna Zentaris’ stock jumped 6.25% Monday, to close the day at $2.04. The stock recorded a trading volume of 700 shares, which was below its three months average volume of 10,154 shares. In the last year, Aeterna Zentaris’ shares have traded in a range of 1.10 – 5.06. The share price has gained 85.45% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $1.95 is below its 200-day moving average of $2.47. Shares of Aeterna Zentaris have fallen approximately 31.54 percent year-to-date.

Access RDI’s Aeterna Zentaris Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AEZS.TO

On Monday, shares of Medicure recorded a trading volume of 80,900 shares, which was above the three months average volume of 23,293 shares. The stock ended the day 8.44% lower at 6.40. The stock is currently trading 30.43% below its 52 week high with a 52 week trading range of 6.00 – 9.20. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $6.91 is below its 200-day moving average of $7.44. Shares of Medicure are trading at a Price to Earnings ratio of 7.21. Shares of Medicure have fallen approximately 14.09 percent year-to-date.

Access RDI’s Medicure Inc. Research Report at:
https://rdinvesting.com/news/?ticker=MPH.V

Our Actionable Research on Hamilton Thorne Ltd. (TSXV :HTL.V), Hemostemix Inc. (TSXV :HEM.V), Aeterna Zentaris Inc. (TSX :AEZS.TO) and Medicure Inc. (TSXV :MPH.V) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 497150